Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML
August 25th 2017
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.